COMIRNATY Omicron XBB.1.5 (Omicron XBB.1.5-adapted monovalent COVID-19 vaccine) / BioNTech, Pfizer - LARVOL DELTA

Variant-adapted COVID-19 vaccine boosters enhance humoral immunity and limit IgG4 accumulation in solid cancer patients. (PubMed, Front Immunol) - "We investigated the humoral response following the administration of the fourth and fifth dose of the Comirnaty Omicron XBB.1.5 mRNA vaccine in 48 patients with solid tumors undergoing active or recent anticancer treatment, compared with age-matched controls (n=24). It seems that variant-adapted formulations may mitigate IgG4 accumulation, thus ideally moderating tolerance associated with IgG4 by introducing antigenic novelty. These findings support continued booster administration and monitoring of humoral responses in oncologic populations."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor

Protection conferred by the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine to patients hospitalized with COVID-19 in Greece in 2023-2024. (PubMed, Infect Dis Now) - "In comparison with unvaccinated individuals, the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine conferred significant protection against in-hospital mortality and reduced length of stay to COVID-19 patients hospitalized in Greece during the 2023-2024 season."

Journal • Critical care • Infectious Disease • Novel Coronavirus Disease

Immunogenicity of the Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in patients with cirrhosis. (PubMed, Scand J Gastroenterol) - " A fifth mRNA-based COVID-19 booster dose significantly augments both humoral and cellular immunity in patients with liver cirrhosis. These findings support the use of a single annual booster dose to maintain adequate immune protection in this vulnerable population."

Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Novel Coronavirus Disease • IL2

Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey. (PubMed, J Infect) - "These findings provide important insights into the effectiveness of targeted vaccine strategies in the context of an evolving pandemic. As SARS-CoV-2 continues to mutate, adaptive approaches in vaccine design and public health policy will be key to addressing emerging variants and protecting high-risk groups."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation. (PubMed, Sci Rep) - "In a population of long-term allo-HSCT survivors, the majority of whom had a prior confirmed COVID-19 infection, both pre- and post-booster immune responses were robust. However, patients undergoing immunosuppressive treatment for GvHD exhibited significantly weaker responses."

Journal • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Transplantation

Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccination. (PubMed, J Infect) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Andusomeran and raxtozinameran for prevention of COVID-19 disease. (PubMed, Aust Prescr) - No abstract available

Journal • Review • Infectious Disease • Novel Coronavirus Disease

I-SPARC: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (clinicaltrials.gov) - P4 | N=152 | Terminated | Sponsor: Jules Bordet Institute | N=440 ➔ 152 | Trial completion date: Dec 2024 ➔ Jan 2024 | Recruiting ➔ Terminated; The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years.

Enrollment change • Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

COVID-19 Vaccines in Children. (PubMed, J Clin Med) - "Recently, recommendations for COVID-19 vaccination were updated accordingly to the 2023-2024 Omicron-XBB.1.5-adapted monovalent COVID-19 vaccine to provide heightened protection against currently circulating SARS-CoV-2 XBB-sublineage variants. COVID-19 vaccines have proven to be safe, efficacious, and effective at protecting against COVID-19 and preventing severe illness in children and adolescents."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Respiratory Diseases

I-SPARC: COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (clinicaltrials.gov) - P4 | N=440 | Recruiting | Sponsor: Jules Bordet Institute

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union (GlobeNewswire) - "Pfizer Inc...and BioNTech SE...announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) administered as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history....The CHMP’s recommendation is based on the full body of previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the COVID-19 vaccines by Pfizer and BioNTech."

European regulatory • Infectious Disease • Novel Coronavirus Disease